keyword
MENU ▼
Read by QxMD icon Read
search

Chronic kidney disease cardiovascular mortality

keyword
https://www.readbyqxmd.com/read/28350620/treatment-of-uncomplicated-hypertension-is-associated-with-a-reduction-in-cardiovascular-mortality-a-korean-national-cohort-study
#1
Chan J Lee, Jinseub Hwang, Jaewon Oh, Sang-Hak Lee, Seok-Min Kang, Donghoon Choi, Hyeon-Chang Kim, Sungha Park
BACKGROUND: Although the benefit of hypertension treatment is well established in high-risk patients, there is a paucity of evidence regarding the benefit of treatment in patients with uncomplicated hypertension. METHODS: Hypertensive adult patients were selected from the Korea National Health Insurance Sample Cohort in 2002 and were followed until 2013. Patients with a diagnosis of heart failure, coronary artery disease, stroke, malignancy, diabetes, or chronic kidney disease were excluded...
May 2017: Journal of Hypertension
https://www.readbyqxmd.com/read/28342643/the-influence-of-pre-left-ventricular-assist-device-lvad-implantation-glomerular-filtration-rate-on-long-term-lvad-outcomes
#2
Burhan Mohamedali, Geetha Bhat
BACKGROUND: Chronic kidney disease (CKD) is a known predictor for adverse outcomes in patients with advanced heart failure requiring left ventricular assist devices (LVADs). The effect of pre-LVAD glomerular filtration rate (GFR) on post-LVAD outcomes in CKD patients is not completely understood. Additionally, a subset of patients improve their GFR after LVAD placement. In this study we sought to determine the effects of pre-LVAD GFR on post-LVAD outcomes. METHODS: Two hundred and seventy consecutive patients with LVADs were enrolled...
February 17, 2017: Heart, Lung & Circulation
https://www.readbyqxmd.com/read/28340216/meta-analysis-of-statins-in-chronic-kidney-disease-who-benefits
#3
C M Messow, C Isles
Background: Attempts to reduce the burden of vascular disease in advanced chronic kidney disease (CKD) by control of lipids have not been as successful as predicted. Aim: : To determine the extent to which the effectiveness of statins varies by kidney class. Design: Meta-analysis. Methods: We selected randomized trials of statin vs. placebo that gave outcomes for CKD3 (eGFR 30-59 ml/min), CKD4 (eGFR 15-29 ml/min), CKD5 (eGFR < 15 ml/min)/5D(dialysis) and transplant patients separately...
March 14, 2017: QJM: Monthly Journal of the Association of Physicians
https://www.readbyqxmd.com/read/28339837/vitamin-d-treatment-attenuates-cardiac-fgf23-fgfr4-signaling-and-hypertrophy-in-uremic-rats
#4
Maren Leifheit-Nestler, Alexander Grabner, Laura Hermann, Beatrice Richter, Karin Schmitz, Dagmar-Christiane Fischer, Christopher Yanucil, Christian Faul, Dieter Haffner
Background.: Vitamin D deficiency and excess of circulating fibroblast growth factor 23 (FGF23) contribute to cardiovascular mortality in patients with chronic kidney disease (CKD). FGF23 activates FGF receptor 4 and (FGFR4) calcineurin/nuclear factor of activated T cells (NFAT) signaling in cardiac myocytes, thereby causing left ventricular hypertrophy (LVH). Here, we determined if 1,25-dihydroxyvitamin D (calcitriol) inhibits FGF23-induced cardiac signaling and LVH. Methods...
February 23, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/28337344/is-fibroblast-growth-factor-23-the-leading-cause-of-increased-mortality-among-chronic-kidney-disease-patients-a-narrative-review
#5
REVIEW
Usama A Sharaf El Din, Mona M Salem, Dina O Abdulazim
The death rate among chronic kidney disease patients is the highest compared to other chronic diseases. 60% of these fatalities are cardiovascular. Cardiovascular calcifications and chronic inflammation affect almost all chronic kidney disease patients and are associated with cardiovascular mortality. Fibroblast growth factor 23 is associated with vascular calcification. Systemic inflammation in chronic kidney disease patients is multifactorial. The role of systemic inflammation in the pathogenesis of vascular calcification was recently reappraised...
May 2017: Journal of Advanced Research
https://www.readbyqxmd.com/read/28333114/inflammatory-cytokines-as-uremic-toxins-ni-son-todos-los-que-estan-ni-estan-todos-los-que-son
#6
REVIEW
Esmeralda Castillo-Rodríguez, Soledad Pizarro-Sánchez, Ana B Sanz, Adrian M Ramos, Maria Dolores Sanchez-Niño, Catalina Martin-Cleary, Beatriz Fernandez-Fernandez, Alberto Ortiz
Chronic kidney disease is among the fastest growing causes of death worldwide. An increased risk of all-cause and cardiovascular death is thought to depend on the accumulation of uremic toxins when glomerular filtration rate falls. In addition, the circulating levels of several markers of inflammation predict mortality in patients with chronic kidney disease. Indeed, a number of cytokines are listed in databases of uremic toxins and uremic retention solutes. They include inflammatory cytokines (IL-1β, IL-18, IL-6, TNFα), chemokines (IL-8), and adipokines (adiponectin, leptin and resistin), as well as anti-inflammatory cytokines (IL-10)...
March 23, 2017: Toxins
https://www.readbyqxmd.com/read/28332417/cost-effectiveness-of-angiotensin-converting-enzyme-inhibitors-versus-angiotensin-ii-receptor-blockers-as-first-line-treatment-in-autosomal-dominant-polycystic-kidney-disease
#7
L A Clark, S Whitmire, S Patton, C Clark, C M Blanchette, R Howden
INTRODUCTION: Autosomal dominant polycystic kidney disease (ADPKD) is a rare kidney disorder impacting approximately 1:2500 individuals among the general US population. Hypertension is a significant predictor of ADPKD progression and risk factor for development of cardiovascular disease (CVD), the most common cause for mortality among ADPKD patients. Angiotensin-converting enzymes inhibitors (ACE-I) are widely used as first-line treatment in ADPKD for the management of hypertension. However, their cost-effectiveness relative to other hypertensive medications, such as angiotensin II receptor blockers (ARB) has never been assessed...
March 23, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28329057/coronary-artery-calcification-and-risk-of-cardiovascular-disease-and-death-among-patients-with-chronic-kidney-disease
#8
Jing Chen, Matthew J Budoff, Muredach P Reilly, Wei Yang, Sylvia E Rosas, Mahboob Rahman, Xiaoming Zhang, Jason A Roy, Eva Lustigova, Lisa Nessel, Virginia Ford, Dominic Raj, Anna C Porter, Elsayed Z Soliman, Jackson T Wright, Myles Wolf, Jiang He
Importance: Coronary artery calcification (CAC) is highly prevalent in dialysis-naive patients with chronic kidney disease (CKD). However, there are sparse data on the association of CAC with subsequent risk of cardiovascular disease and all-cause mortality in this population. Objective: To study the prospective association of CAC with risk of cardiovascular disease and all-cause mortality among dialysis-naive patients with CKD. Design, Setting, and Participants: The prospective Chronic Renal Insufficiency Cohort study recruited adults with an estimated glomerular filtration rate of 20 to 70 mL/min/1...
March 22, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/28327102/higher-plasma-transforming-growth-factor-tgf-%C3%AE-is-associated-with-kidney-disease-in-older-community-dwelling-adults
#9
Tapan Mehta, Petra Buzkova, Jorge R Kizer, Luc Djousse, Michel Chonchol, Kenneth J Mukamal, Michael Shlipak, Joachim H Ix, Diana Jalal
BACKGROUND: TGF-β is induced in the vasculature with aging suggesting that high plasma TGF-β levels may be a risk factor for chronic kidney disease (CKD) in older adults. METHODS: We conducted a cross-sectional analysis of the association between plasma TGF-β levels and CKD including data for 1722 older adults who had participated in the 1996/97 visit of the Cardiovascular Health Study (CHS). Prevalent CKD was defined as eGFR < 60 mL/min/1.73 m(2) or urinary albumin/creatinine ratio (ACR) ≥30 mg/g...
March 21, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28326604/cardiac-imaging-in-chronic-kidney-disease-patients
#10
Paolo Raggi, Nikolaos Alexopoulos
Cardiovascular disease is highly prevalent and it is associated with high morbidity and mortality rates in patients with chronic kidney disease (CKD). The implementation of various imaging modalities may help to risk stratify these patients with a potential ease on the burden of complications and the rising costs of care. In this article we review some of the modern imaging techniques to diagnose cardiac disease in patients affected by CKD.
March 21, 2017: Seminars in Dialysis
https://www.readbyqxmd.com/read/28321399/renocardiovascular-biomarkers-from-the-perspective-of-managing-chronic-kidney-disease-and-cardiovascular-disease
#11
REVIEW
Shinichiro Niizuma, Yoshitaka Iwanaga, Takaharu Yahata, Shunichi Miyazaki
Mortality among the patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) remains high because of the very high incidence of cardiovascular disease (CVD) such as coronary artery disease, cardiac hypertrophy, and heart failure. Identifying CVD in patients with CKD/ESRD remains a significant hurdle and the early diagnosis and therapy for CVD is crucial in these patients. Therefore, it is necessary for the better management to identify and utilize cardiovascular (CV) biomarkers in profiling CVD risk and enabling stratification of early mortality...
2017: Frontiers in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28318510/comparative-efficacy-of-coronary-revascularization-procedures-for-multivessel-coronary-artery-disease-in-patients-with-chronic-kidney-disease
#12
John K Roberts, Sunil V Rao, Linda K Shaw, Dianne S Gallup, Oscar C Marroquin, Uptal D Patel
Patients with chronic kidney disease (CKD) are at increased risk of cardiovascular disease and death, yet little data exist regarding the comparative efficacy of coronary revascularization procedures in CKD patients with multivessel disease. We created a cohort of 4,687 adults who underwent cardiac catheterization, had a serum creatinine value measured within 30 days, and had more than one vessel with ≥50% stenosis. We used Cox proportional hazard regression modeling weighted by the inverse probability of treatment to examine the association between 4 treatment strategies (medical management, percutaneous coronary intervention [PCI] with bare metal stent, PCI with drug-eluting stent, and coronary artery bypass grafting [CABG]) and mortality among patients across categories of estimated glomerular filtration rate; secondary outcome was a composite of mortality, myocardial infarction, or revascularization...
February 9, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28317478/homocysteine-and-non-cardiac-vascular-disease
#13
Niki Katsiki, Pablo Perez-Martinez, Dimitri P Mikhailidis
Elevated homocysteine (Hcy) levels are predictors of cardiovascular disease (CVD). Hyperhomocysteinemia has also been associated with total and CVD mortality. However, whether Hcy is just a marker or plays a causal role in CVD remains to be elucidated. In this narrative review, we discuss the associations between Hcy and non-cardiac vascular diseases, namely stroke, peripheral artery disease (PAD), carotid artery disease, chronic kidney disease (CKD), atherosclerotic renal artery stenosis (ARAS), abdominal aortic aneurysm (AAA) and erectile dysfunction (ED)...
March 17, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28302014/role-of-hepcidin-25-in-chronic-kidney-disease-anemia-and-beyond
#14
Norishi Ueda, Kazuya Takasawa
Iron is an essential element for all living organisms, but produces toxic oxidants. Thus, iron homeostasis is tightly regulated in mammals. Hepcidin-25 (hepcidin) has emerged as a molecule that regulates iron metabolism. Binding of hepcidin to its receptor, ferroportin, inhibits intestinal iron absorption and iron efflux from hepatocytes and macrophages. Decreased hepcidin enhances iron absorption and efflux. Hepcidin could be predictive of iron status and the response to iron supplementation or erythropoietin-stimulating agents...
March 16, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28299616/promise-of-sglt2-inhibitors-in-heart-failure-diabetes-and-beyond
#15
REVIEW
Pieter Martens, Chantal Mathieu, Frederik H Verbrugge
This review provides mechanistic insight in the pleiotropic effects of sodium-glucose transporter-2 (SGLT-2) inhibitors with particular interest to the pathophysiology of heart failure. The SGLT-2 inhibitor empagliflozin has recently demonstrated an unprecedented 38% reduction in cardiovascular mortality in patients with diabetes. Despite modest effects on long-term glycemic control, highly significant reductions in heart failure admissions and end-stage kidney disease were observed. SGLT-2 inhibitors are the latest approved class of glucose-lowering agents...
March 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28298956/phosphorus-regulation-in-chronic-kidney-disease
#16
Wadi N Suki, Linda W Moore
Serum phosphorus levels stay relatively constant through the influence of multiple factors-such as parathyroid hormone, fibroblast growth factor 23, and vitamin D-on the kidney, bone, and digestive system. Whereas normal serum phosphorus ranges between 3 mg/dL to 4.5 mg/dL, large cross-sectional studies have shown that even people with normal kidney function are sometimes found to have levels ranging between 1.6 mg/dL and 6.2 mg/dL. While this may partially be due to diet and the factors mentioned above, total understanding of these atypical ranges of serum phosphorus remains uncertain...
October 2016: Methodist DeBakey Cardiovascular Journal
https://www.readbyqxmd.com/read/28294047/klotho-fgf23-cardiovascular-disease-and-vascular-calcification-black-or-white
#17
Giuseppe Cianciolo, Andrea Galassi, Irene Capelli, Roberto Schillaci, Gaetano La Manna, Mario Cozzolino
Patients affected by Chronic Kidney Disease and Mineral Bone Disorder (CKD-MBD) have a high risk of cardiovascular (CV) mortality that is poorly explained by traditional risk factors. The newest medical treatments for CKD-MBD have been associated with encouraging, but still inconsistent, improvement in CV disease complications and patient survival. A better understanding of the biomarkers and mechanisms of left ventricular hypertrophy (LVH), atherosclerosis, and vascular calcification (VC) may help with diagnosis and treatment of the organ damage that occurs secondary to CKD-MBD, thus improving survival...
March 9, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28286758/role-of-vitamin-d-in-uremic-vascular-calcification
#18
REVIEW
Yi-Chou Hou, Wen-Chih Liu, Cai-Mei Zheng, Jing-Quan Zheng, Tzung-Hai Yen, Kuo-Cheng Lu
The risk of cardiovascular death is 10 times higher in patients with CKD (chronic kidney disease) than in those without CKD. Vascular calcification, common in patients with CKD, is a predictor of cardiovascular mortality. Vitamin D deficiency, another complication of CKD, is associated with vascular calcification in patients with CKD. GFR decline, proteinuria, tubulointerstitial injury, and the therapeutic dose of active form vitamin D aggravate vitamin D deficiency and reduce its pleiotropic effect on the cardiovascular system...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28283484/comparative-effectiveness-and-safety-of-erythropoiesis-stimulating-agents-biosimilars-vs-originators-in-clinical-practice-a-population-based-cohort-study-in-italy
#19
Francesco Trotta, Valeria Belleudi, Danilo Fusco, Laura Amato, Alessandra Mecozzi, Flavia Mayer, Massimo Sansone, Marina Davoli, Antonio Addis
OBJECTIVES: To evaluate the benefit/risk profile of epoetin α biosimilar with the erythropoiesis-stimulating agents (ESAs) originators when administered to naïve patients from clinical practice. DESIGN: Population-based observational cohort study. SETTING: All residents in the Lazio Region, Italy, with chronic kidney disease (CKD) or cancer retrieved from the Electronic Therapeutic Plan (ETP) Register for ESA between 2012 and 2014. PARTICIPANTS: Overall, 13 470 incident ESA users were available for the analysis, 8161 in the CKD and 5309 in the oncology setting, respectively...
March 10, 2017: BMJ Open
https://www.readbyqxmd.com/read/28281103/current-evidence-on-vitamin-d-deficiency-and-kidney-transplant-what-s-new
#20
REVIEW
Gerardo Sarno, Riccardo Nappi, Barbara Altieri, Giacomo Tirabassi, Emanuele Muscogiuri, Gianmaria Salvio, Stavroula A Paschou, Aristide Ferrara, Enrico Russo, Daniela Vicedomini, Cerbone Vincenzo, Andromachi Vryonidou, Silvia Della Casa, Giancarlo Balercia, Francesco Orio, Paride De Rosa
Kidney transplant is the treatment of choice for end-stage chronic kidney disease. Kidneys generate 1,25-dihydroxyvitamin D (calcitriol) from 25-hydroxyvitamin D (calcidiol) for circulation in the blood to regulate calcium levels. Transplant patients with low calcidiol levels have an increased risk of metabolic and endocrine problems, cardiovascular disease, type 2 diabetes mellitus, poor graft survival, bone disorders, cancer, and mortality rate. The recommended calcidiol level after transplant is at least 30 ng/mL (75 nmol/L), which could require 1000-3000 IU/d vitamin D3 to achieve...
March 9, 2017: Reviews in Endocrine & Metabolic Disorders
keyword
keyword
42560
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"